This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose.
Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.

开始日期2026-10-01

申办/合作机构

Duke University

[+1]

CTR20262452

/ Recruiting临床4期

评估高血糖素鼻用粉雾剂在糖尿病患者中治疗2级或3级低血糖事件疗效与安全性的开放、多中心、前瞻性临床研究

评估高血糖素鼻用粉雾剂治疗2级或3级低血糖的有效性，并评价在实际使用中高血糖素鼻用粉雾剂治疗2级或3级低血糖的易用性和安全性

开始日期2026-07-09

申办/合作机构

礼来苏州制药有限公司

[+3]

NCT07427251

/ Recruiting临床4期

Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People With Type 1 Diabetes

The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.
The primary endpoint is the difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.

开始日期2026-04-27

申办/合作机构

Steno Diabetes Center Copenhagen

100 项与胰高血糖素相关的临床结果

登录后查看更多信息

100 项与胰高血糖素相关的转化医学

登录后查看更多信息

100 项与胰高血糖素相关的专利（医药）

登录后查看更多信息

7,224

项与胰高血糖素相关的文献（医药）

2026-08-04·Journal of the American Heart Association

Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon‐Like Peptide‐1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus

Review

作者: Michos, Erin D. ; Kushner, Pamela R.

Cardio–kidney–metabolic diseases including obesity, metabolic dysfunction–associated liver disease, and type 2 diabetes have reached pandemic prevalence, fueling the search for new treatments for these conditions, given their associated complications, notably cardiovascular disease. Dual agonists of the glucagon and glucagon‐like peptide (GLP‐1) receptors are promising. Certain GLP‐1 receptor monoagonists are indicated for treatment of type 2 diabetes, obesity, and metabolic dysfunction–associated steatotic liver disease; and for reducing cardiovascular events in type 2 diabetes or obesity and cardiorenal events in people with type 2 diabetes and chronic kidney disease. GCGR (glucagon receptor)/GLP‐1 receptor dual agonists may have additional efficacy, given emerging evidence that glucagon regulates energy balance and lipid metabolism as well as glucose homeostasis. However, putative cardiac effects of glucagon highlight cardiovascular safety considerations for dual agonists. Although unequivocal evidence that the GCGR is expressed in the human heart is lacking, high‐dose exogenous glucagon has acute chronotropic, inotropic, and hypertensive effects. Clinical studies of GCGR/GLP‐1 receptor dual agonists (eg, mazdutide, survodutide) have generally found that they increased heart rate to a similar extent as GLP‐1 receptor monoagonists (which are cardioprotective despite such chronotropic effects). Mazdutide and survodutide also reduced blood pressure and hyperglycemia. However, at least 1 other dual agonist was discontinued, partly due to unacceptably large increases in heart rate and prolongation of the corrected QT interval. These between‐compound differences may reflect different potencies for activating the GCGR and GLP‐1 receptors. Cardiovascular effects of GCGR signaling by dual agonists should be clarified per compound by ongoing clinical trials, notably the cardiovascular outcomes trial SYNCHRONIZE‐CVOT (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity) and thorough corrected QT study of survodutide.

2026-08-01·DIABETES OBESITY & METABOLISM

Dose–Response Effect of Glucagon on Glucose, Beta‐Cell Secretion and Metabolism in Healthy Individuals

Article

作者: Sturlaugsson Jóhönnuson, Elvar Már ; Wewer Albrechtsen, Nicolai J. ; Kjeldsen, Sasha Alexandra Sampson ; Hansen, Nina Lerberg ; Brock, Sophie Betty

ABSTRACT:

Aim:

Glucagon is a key regulator of glucose and energy metabolism, yet the dose–response effects of glucagon on markers of metabolism in humans are not fully characterised. We investigated the dose‐dependent effects of glucagon on glucose metabolism, β‐cell secretion and markers of hepatic metabolism in healthy adults.

Materials and Methods:

Fifteen healthy, lean adults underwent a 180‐min stepwise intravenous infusion of native human glucagon at six increasing doses (0.01, 0.1, 0.5, 1, 10 and 50 ng × kg −1 × min −1 ). Plasma glucose, insulin, C‐peptide, cyclic AMP (cAMP), non‐esterified fatty acids, triglycerides, total amino acids and urea were measured repeatedly throughout the study.

Results:

Plasma glucose increased in a dose‐dependent manner, with significant stepwise elevations observed from intermediate infusion rates and reaching peak levels at supraphysiological glucagon levels. Insulin and C‐peptide levels rose markedly, reflecting β‐cell activation. Plasma cAMP increased only during the highest glucagon infusion rate, despite earlier metabolic responses. Plasma non‐esterified fatty acids, triglycerides and total amino acids declined at higher glucagon doses, whilst plasma urea decreased gradually from the second infusion rate onward.

Conclusion:

Infusion of glucagon results in dose‐dependent metabolic effects in healthy humans. The differential timing of glucose, lipid and amino acid responses relative to systemic cAMP elevations could be consistent with pathway‐specific activation thresholds rather than uniform signalling. These findings provide new insights into human glucagon physiology with potential relevance for metabolic diseases.

2026-08-01·Obesity Reviews

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Article

作者: Sarah Cawsey ; Flavio T. Vieira ; Manfred J. Muller ; Carla M. Prado ; Steven B. Heymsfield ; Giovanna G. L. Bergamasco ; Andrea M. Haqq ; ZhiDi Deng ; Melania Manco

ABSTRACT:

Introduction:

Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear.

Methods:

In this scoping review, we searched MEDLINE, EMBASE, CINAHL, Web of Science, ProQuest, and Cochrane Library (inception to October 2025) for studies that investigated the effects of GLP‐1RA (mono or combination therapy) on EE in humans.

Results:

Twenty‐three studies were included, 10 assessed GLP‐1RA monotherapy (4 exenatide, 4 liraglutide, 1 semaglutide, 1 beinaglutide) and 13 combination therapy (11 dual, 2 triple agonists); drug regimen heterogeneity was high. Most studies assessed resting metabolic rate (RMR); 4 used 24‐h whole‐room indirect calorimetry; and none applied doubly labeled water. Eight studies (34.8%) concluded that GLP‐1RA mono or combination therapy had non‐significant effects on EE. Combination with glucagon produced varied impacts on EE components (RQ [ n = 3], RMR [ n = 1], and sleep metabolic rate [n = 1]), whereas combination with glucose‐dependent insulinotropic polypeptide (GIP) decreased RQ and increased fat utilization ( n = 1). Eleven studies (47.8%) produced inconclusive results due to the applied statistical analyses.

Conclusion:

Acute or chronic GLP‐1RA monotherapy does not appear to impact EE independent of weight loss. Combining GLP‐1RA with glucagon or GIP may impact EE in different ways, requiring further exploration.

692

项与胰高血糖素相关的新闻（医药）

2026-09-07

·搜狐新闻

InnoScan 1100 0.5微米/高分辨率/三色荧光/基因芯片/蛋白芯片/糖芯片/化合物芯片/细胞组织芯片/超高密度微阵列生物芯片扫描分析仪

法国 Innopsys 公司成立于1999年，总部位于法国的图卢兹，并设立美国芝加哥分部 20多年专注于激光共聚焦微阵列生物芯片扫描分析仪荧光检测硬件和软件的自主开发与生产作为超高分辨率微阵列生物芯片扫描分析仪的制造厂商，全球装机客户已超过600家 InnoScan 1100 0.5微米/高分辨率/三色荧光微阵列芯片扫描仪采用先进的激光共聚焦扫描光路和高灵敏度PMT检测器，进行多通道荧光检测有效降低荧光光漂白现象以及信号损失，还可有效缩短扫描时间 01 技术原理共聚焦光路实时共聚焦激光光路，保证高分辨率和高灵敏度，扫描结果更高清动态范围广动态范围可扩展至10⁶ bit，避免过度饱和或低信号假阴性 02 产品特点高灵敏度：实时共聚焦光路，极大提高灵敏度高分辨率： 0.5μm/pixel-40μm/pixel可调高信噪比：线扫描方式，图片无拼痕、无需阴影矫正，有效降低荧光的光漂白现象及信号损失高通量：可实现24片玻片自动进样激光光源：488nm(蓝)，532nm(绿)和635nm(红) 扫描通道：可实现三通道同时扫描，三个独立的PMT可同步检测扫描速度快：在1μm/pixel分辨率下，10.5min即可完成22mmX22mm芯片面积的扫描 03 应用方向寡核苷酸芯片、核酸芯片、基因芯片扫描：对基因功能分析、基因表型分析、基因突变分析等蛋白质芯片、多肽芯片、抗原抗体芯片扫描：对蛋白表达水平检测、功能蛋白筛选、蛋白质相互作用等糖芯片、多糖芯片、糖蛋白芯片扫描：进行糖功能学、糖蛋白、植物凝集素等研究小分子化合物芯片扫描：进行配体筛选、药物研发、疾病靶点筛选细胞组织芯片扫描：细胞代谢机制、信号传导机制；组织间蛋白表达差异等 04 应用案例蛋白质芯片扫描分析-牙周炎机制研究作者：北京大学口腔预防学系国家口腔临床研究中心应用：使用法国Innopsys激光共聚焦荧光微阵列生物芯片扫描仪进行荧光信号检测及分析，为探究枯草芽孢杆菌 R0179 是否能逆转牙龈卟啉单胞菌刺激诱导的 TLR、下游 p-NF-κB 及促炎细胞因子表达变化。 Inactivated Bacillus subtilis R0179 Inhibits Porphyromonas GingivalisInduced Gingival Inflammation Via TLR2/NF-κB Signaling in a Murine Model of Periodontitis（Inflammation，2025）蛋白质芯片扫描分析-结直肠癌靶点发现作者：南方医科大学联合广州医科大学附属肿瘤医院应用：使用法国Innopsys激光共聚焦荧光微阵列生物芯片扫描仪进行荧光信号检测及分析，揭示肠道微生物代谢产物4-HPA通过激活JAK2/STAT3信号通路，促进结直肠癌细胞分泌趋化因子CXCL3，从而招募免疫抑制性的多形核髓源性抑制细胞（PMN-MDSCs），抑制CD8T细胞的抗肿瘤活性，最终促进结直肠癌进展及免疫抑制微环境的形成。 Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs（J Clin Invest，2025）小分子化合物芯片扫描分析-RNA酶结合位点筛选作者：美国国家癌症研究所化学生物学实验室应用：作者使用微阵列生物芯片扫描分析仪-InnoScan 1100AL在635nm处对小分子化合物微阵列芯片进行荧光信号扫描和分析，通过研究发现了一种可以下调DHX15蛋白表达的化合物，该方法为新药研发过程中先导化合物的发现提供了一种新的研究策略。 Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-quadruplex（ACS Medicinal Chemistry Letters, 2025）多糖芯片扫描分析-流感病毒感染研究作者：西北大学糖生物学与糖工程重点实验室应用：作者将羊栖菜来源岩藻多糖（硫酸化多糖）制备为寡糖芯片，孵育甲型流感病毒血凝素（HA）蛋白，荧光标记后扫描，分析多糖与病毒蛋白的结合活性。 Preparation of fucoidan oligosaccharides from Sargassum fusiforme using the “layer by layer” degradation strategy and their binding study with HA proteins of influenza A viruses（Carbohydrate Polymers， 2025）基因芯片扫描分析-SARS病毒突变体检测作者：意大利国家化学科学与技术研究所应用：作者使用微阵列生物芯片扫描分析仪-InnoScan，对核酸芯片进行荧光信号扫描和分析，对SARS病毒的突变体进行分型检测 Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos（Biosensors , 2023）单细胞scWestern免疫印迹芯片扫描分析检测采用单细胞蛋白免疫印迹检测技术（scWesterns）对单细胞进行靶蛋白检测细胞芯片扫描作者：法国国家科学研究中心应用：作者使用微阵列生物芯片扫描分析仪-InnoScan，对细胞微阵列芯片进行荧光信号扫描和分析，用于制备细胞芯片方法学开发，细胞核用DRAQ5™染料（蓝色）标记，细胞质用GFP 蛋白（绿色）标记。 Dynamic inking of large-scale stamps for multiplexed microcontact printing and fabrication of cell microarrays（PLOS ONE , 2018）组织芯片扫描乳腺癌组织样本来源于Gustave Roussy Institute (France) 注：IS 1100 AL ，0.5µm/pixel 分辨率进行扫描. Panel A：绿色荧光染料标记细胞膜；红色染料标记血管 Panel B：绿色荧光染料标记细胞膜；蓝色染料标记CD45淋巴球 Panel C：2µm/pixel分辨率，扫描整张组织芯片 05 代表客户发表文献 Han, M.-M., et al., 8-Oxoguanine Modifications in Peripheral Leukocyte microRNAs Promote Age-related Inflammation by Remodeling Gene Regulatory Networks. 中国医学科学院老年医学研究所蛋白芯片 Li, J., et al., Comprehensive single-cell analysis deciphered the immunoregulatory mechanism of TPPU in alleviating sepsis-related acute liver injury. 郑州大学第一附属医院蛋白芯片 Zhao, Z., et al., Development and Validation of a Diagnostic Model for Stanford Type B Aortic Dissection Based on Proteomic Profiling. 河北医科大学第二医院蛋白芯片 Li, Z., et al., Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. 中国医学科学院北京协和医院蛋白芯片 Bi, Y., et al., Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells. Cell Metabolism. 中国科学院生物物理研究所蛋白芯片 Liao, Q., et al., Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. 南方医科大学基础医学院蛋白芯片 Hu, W., et al., Identification and Validation of Key Amino Acids in IgE Linear Epitopes of β-Lactoglobulin: Comparison of Recognition Patterns of Chinese Bovine Milk-Allergic Sera with Different Symptoms. 南昌大学蛋白芯片 Zhang, X., et al., A machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response. 兰州大学蛋白芯片 Liu, Y., et al., Isolation, structural characterization of natural chondroitin sulfate oligosaccharides and their binding study with anti-angiogenic factors. 西北大学多糖芯片 Better, J., et al., Cell type–specific efferocytosis determines functional plasticity of alveolar macrophages. 德国吉森尤斯图斯 - 李比希大学核酸芯片 Sidharthan, V., et al., Use of a small molecule microarray screen to identify inhibitors of the catalytic RNA subunit of Methanobrevibacter smithii RNase P 美国国家癌症研究所小分子化合物芯片 Tsuno, T., et al., Imeglimin suppresses glucagon secretion and induces a loss of alpha cell identity.群马大学分子与细胞调控研究所单细胞免疫印迹芯片 Foncy, J., et al., Dynamic inking of large-scale stamps for multiplexed microcontact printing and fabrication of cell microarrays. 法国图卢兹大学细胞芯片环亚产品环亚生物科技有限公司（APG BIO Ltd）成立于2011年，专注于引进国外创新技术和高品质仪器设备。返回搜狐，查看更多

寡核苷酸临床申请

2026-09-07

·恒瑞医药

2026 EASD前瞻｜恒瑞医药口服小分子GLP-1RA、胰岛素周制剂、GLP-1/GIP双受体激动剂、GLP-1/GIP/GCG三受体激动剂等多项重磅研究入选LBA

第62届欧洲糖尿病研究协会（EASD）年会将于2026年9月28日至10月2日在意大利米兰举行。本次大会，恒瑞医药多项重磅研究入选LBA（最新突破摘要），包括：口服小分子GLP-1RA HRS-7535两项2型糖尿病Ⅲ期研究数据、基础胰岛素周制剂SHR-3167两项2型糖尿病Ⅱ期研究数据、GLP-1/GIP双受体激动剂瑞普泊肽注射液（研发代号HRS9531；大中华区外称KAI-9531，由Kailera Therapeutics开发）用于肥胖合并多内分泌代谢卵巢综合征（PMOS）的Ⅱ期研究数据、GLP-1/GIP/GCG三受体激动剂HRS-4729一项Ⅰ期研究数据1。此外，Kailera Therapeutics的一项瑞普泊肽注射液Ⅰ期研究数据也将在本次大会上由Kailera公布1。口服小分子GLP-1RA HRS-7535 中稿类型：Short Oral Discussions 摘要号：LBA 39 英文标题：Oral small-molecule GLP-1RA HRS-7535 as monotherapy in Chinese adults with early type 2 diabetes: the OUTSTAND-1 Phase 3 trial. 中文标题：口服小分子GLP-1受体激动剂HRS-7535单药治疗中国成人早期2型糖尿病：OUTSTAND-1 Ⅲ期临床试验。讲者：于淼，北京协和医院时间：9月29日12:00-13:00 CEST 中稿类型：Orals 摘要号：LBA 10 英文标题：Oral HRS-7535 versus dapagliflozin in Chinese adults with type 2 diabetes inadequately controlled with metformin: the OUTSTAND-2 Phase 3 trial. 中文标题：口服HRS-7535与达格列净在二甲双胍控制不佳的中国成人2型糖尿病患者中的比较：OUTSTAND-2 Ⅲ期临床试验。讲者：郭立新，北京医院时间：9月29日15:30-15:45 CEST 胰岛素周制剂SHR-3167 中稿类型：Short Oral Discussions 摘要号：LBA 97 英文标题：Once-weekly insulin SHR-3167 versus once-daily insulin glargine U100 in type 2 diabetes without previous insulin treatment. 中文标题：每周一次胰岛素SHR-3167与每日一次甘精胰岛素U100在未接受过胰岛素治疗的2型糖尿病患者中的比较。讲者：曾梅芳，恒瑞医药时间：10月1日12:45-13:45 CEST 中稿类型：Short Oral Discussions 摘要号：LBA 96 英文标题：Efficacy and safety of once-weekly insulin SHR-3167 vs daily insulin degludec in type 2 diabetes participants previously treated with basal insulin with or without oral antidiabetic drugs. 中文标题：每周一次胰岛素SHR-3167与每日一次德谷胰岛素在既往接受基础胰岛素（联合或不联合口服降糖药）治疗的2型糖尿病患者中的疗效与安全性。讲者：赵琳，复旦大学附属中山医院时间：10月1日12:45-13:45 CEST GLP-1/GIP双受体激动剂瑞普泊肽注射液中稿类型：Short Oral Discussions 摘要号：LBA 74 英文标题：Efficacy and safety of ribupatide (HRS9531) in participants with obesity and polyendocrine metabolic ovarian syndrome (PMOS): a multicentre, randomised, double-blind, Phase 2 trial. 中文标题：瑞普泊肽（HRS9531）在肥胖合并多内分泌代谢卵巢综合征（PMOS）患者中的疗效与安全性：一项多中心、随机、双盲、Ⅱ期临床试验。讲者：姜宏卫，河南科技大学第一附属医院时间：10月1日12:45-13:45 CEST 中稿类型：Short Oral Discussions 摘要号：756 英文标题：Effect of injection site on the relative bioavailability and safety of ribupatide, a novel dual GLP-1/GIP receptor agonist: Phase 1, randomised, single-dose crossover study results. 中文标题：注射部位对新型GLP-1/GIP双受体激动剂瑞普泊肽相对生物利用度和安全性的影响：一项I期、随机、单剂量交叉研究结果。讲者：Marianne Camargo, Kailera Therapeutics 时间：10月1日12:45-13:45 CEST GLP-1/GIP/GCG三受体激动剂HRS-4729 中稿类型：Short Oral Discussions 摘要号：LBA 41 英文标题：Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomised, double-blind, placebo-controlled Phase 1 study. 中文标题：新型GLP-1/GIP/胰高血糖素三受体激动剂HRS-4729的安全性、耐受性、药代动力学和药效学：一项随机、双盲、安慰剂对照的I期研究。讲者：贺坤，山东第一医科大学附属中心医院时间：9月29日12:00-13:00 CEST 本次大会恒瑞医药GLP-1类产品及胰岛素周制剂多项重磅临床数据集中亮相，充分彰显了中国在代谢病创新药研发领域的学术实力与临床研究能力。恒瑞医药将持续聚焦2026 EASD最新研究进展，为大家带来更多恒瑞重磅研究数据分享，敬请关注。参考来源：1.https://www.easd.org/annual-meeting/easd-2026/programme/ 声明： 1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。 2.恒瑞医药不推荐任何未被批准的药品、适应症的使用。撰稿：非肿瘤医学事务部心血管代谢团队排版：程梦真责编：李玉莹往期精选 | 研发创新 | 中国首个自主研发长效胰岛素类似物！恒瑞医药创新药瑞恒盈®获批上市 | 国际化 | 恒瑞医药与百时美施贵宝达成战略合作协议，携手推进肿瘤学、血液学及免疫学创新疗法创新药出海再下一城！恒瑞医药HER2 ADC瑞康曲妥珠单抗实现海外独家许可 | 重磅奖项 | 再传捷报！恒瑞医药创新药氟唑帕利胶囊（艾瑞颐®）专利荣获中国专利金奖捷报！恒瑞医药创新药海曲泊帕乙醇胺片（恒曲®）专利荣获中国专利金奖 | 社会公益 | 恒瑞医药捐赠1000万港元，驰援香港大埔火灾救助 “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国

临床2期临床3期临床结果

2026-09-07

·微信

InnoScan 710 IR 近红外荧光/低背景/高信噪比/覆膜/微阵列芯片扫描仪/细胞因子/炎症因子检测——覆膜芯片扫描金标准，670/785nm 激光光源

法国 Innopsys 公司成立于1999年，总部位于法国的图卢兹，并设立美国芝加哥分部 20多年专注于激光共聚焦微阵列生物芯片扫描分析仪荧光检测硬件和软件的自主开发与生产作为超高分辨率微阵列生物芯片扫描分析仪的制造厂商，全球装机客户已超过600家 InnoScan 710 IR 近红外荧光/低背景/高信噪比/覆膜/微阵列芯片扫描仪采用先进的激光共聚焦扫描光路和高灵敏度PMT检测器，进行双通道近红外荧光检测有效降低荧光光漂白现象以及信号损失，还可有效缩短扫描时间覆膜芯片可见光波段扫描背景高，信噪比低覆膜芯片 IS-710IR红外波段785nm扫描低背景，高信噪比技术原理共聚焦光路实时共聚焦激光光路，保证高分辨率和高灵敏度，扫描结果更高清动态范围广动态范围可扩展至10⁶ bit，避免过度饱和或低信号假阴性产品特点高灵敏度：实时共聚焦光路，极大提高灵敏度高分辨率： 3μm/pixel-40μm/pixel可调高信噪比：线扫描方式，图片无拼痕、无需阴影矫正，有效降低荧光的光漂白现象及信号损失高通量：可实现24片玻片自动进样双色激光光源：670nm(绿)和785nm(红)双色扫描通道：可实现双色通道同时扫描，两个独立的PMT可同步检测扫描速度快：在10μm/pixel分辨率下，3.55min即可完成一张芯片扫描应用方向寡核苷酸芯片、核酸芯片、基因芯片扫描：对基因功能分析、基因表型分析、基因突变分析等蛋白质芯片、多肽芯片、抗原抗体芯片扫描：对蛋白表达水平检测、功能蛋白筛选、蛋白质相互作用等糖芯片、多糖芯片、糖蛋白芯片扫描：进行糖功能学、糖蛋白、植物凝集素等研究小分子化合物芯片扫描：进行配体筛选、药物研发、疾病靶点筛选细胞组织芯片扫描：细胞代谢机制、信号传导机制；组织间蛋白表达差异等应用案例蛋白质芯片扫描分析-牙周炎机制研究作者：北京大学口腔预防学系国家口腔临床研究中心应用：使用法国Innopsys激光共聚焦荧光微阵列生物芯片扫描仪进行荧光信号检测及分析，为探究枯草芽孢杆菌 R0179 是否能逆转牙龈卟啉单胞菌刺激诱导的 TLR、下游 p-NF-κB 及促炎细胞因子表达变化。 Inactivated Bacillus subtilis R0179 Inhibits Porphyromonas GingivalisInduced Gingival Inflammation Via TLR2/NF-κB Signaling in a Murine Model of Periodontitis（Inflammation，2025）蛋白质芯片扫描分析-结直肠癌靶点发现作者：南方医科大学联合广州医科大学附属肿瘤医院应用：使用法国Innopsys激光共聚焦荧光微阵列生物芯片扫描仪进行荧光信号检测及分析，揭示肠道微生物代谢产物4-HPA通过激活JAK2/STAT3信号通路，促进结直肠癌细胞分泌趋化因子CXCL3，从而招募免疫抑制性的多形核髓源性抑制细胞（PMN-MDSCs），抑制CD8T细胞的抗肿瘤活性，最终促进结直肠癌进展及免疫抑制微环境的形成。 Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs（J Clin Invest，2025）小分子化合物芯片扫描分析-RNA酶结合位点筛选作者：美国国家癌症研究所化学生物学实验室应用：作者使用微阵列生物芯片扫描分析仪-InnoScan 1100AL在635nm处对小分子化合物微阵列芯片进行荧光信号扫描和分析，通过研究发现了一种可以下调DHX15蛋白表达的化合物，该方法为新药研发过程中先导化合物的发现提供了一种新的研究策略。 Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-quadruplex（ACS Medicinal Chemistry Letters, 2025）多糖芯片扫描分析-流感病毒感染研究作者：西北大学糖生物学与糖工程重点实验室应用：作者将羊栖菜来源岩藻多糖（硫酸化多糖）制备为寡糖芯片，孵育甲型流感病毒血凝素（HA）蛋白，荧光标记后扫描，分析多糖与病毒蛋白的结合活性。Preparation of fucoidan oligosaccharides from Sargassum fusiforme using the “layer by layer” degradation strategy and their binding study with HA proteins of influenza A viruses（Carbohydrate Polymers， 2025）基因芯片扫描分析-SARS病毒突变体检测作者：意大利国家化学科学与技术研究所应用：作者使用微阵列生物芯片扫描分析仪-InnoScan，对核酸芯片进行荧光信号扫描和分析，对SARS病毒的突变体进行分型检测 Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos（Biosensors , 2023）单细胞scWestern免疫印迹芯片扫描分析检测采用单细胞蛋白免疫印迹检测技术（scWesterns）对单细胞进行靶蛋白检测代表客户发表文献 Han, M.-M., et al., 8-Oxoguanine Modifications in Peripheral Leukocyte microRNAs Promote Age-related Inflammation by Remodeling Gene Regulatory Networks. 中国医学科学院老年医学研究所蛋白芯片 Li, J., et al., Comprehensive single-cell analysis deciphered the immunoregulatory mechanism of TPPU in alleviating sepsis-related acute liver injury. 郑州大学第一附属医院蛋白芯片 Zhao, Z., et al., Development and Validation of a Diagnostic Model for Stanford Type B Aortic Dissection Based on Proteomic Profiling. 河北医科大学第二医院蛋白芯片 Li, Z., et al., Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. 中国医学科学院北京协和医院蛋白芯片 Bi, Y., et al., Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells. Cell Metabolism. 中国科学院生物物理研究所蛋白芯片 Liao, Q., et al., Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. 南方医科大学基础医学院蛋白芯片 Hu, W., et al., Identification and Validation of Key Amino Acids in IgE Linear Epitopes of β-Lactoglobulin: Comparison of Recognition Patterns of Chinese Bovine Milk-Allergic Sera with Different Symptoms. 南昌大学蛋白芯片 Zhang, X., et al., A machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response. 兰州大学蛋白芯片 Liu, Y., et al., Isolation, structural characterization of natural chondroitin sulfate oligosaccharides and their binding study with anti-angiogenic factors. 西北大学多糖芯片 Better, J., et al., Cell type–specific efferocytosis determines functional plasticity of alveolar macrophages. 德国吉森尤斯图斯 - 李比希大学核酸芯片 Sidharthan, V., et al., Use of a small molecule microarray screen to identify inhibitors of the catalytic RNA subunit of Methanobrevibacter smithii RNase P 美国国家癌症研究所小分子化合物芯片 Tsuno, T., et al., Imeglimin suppresses glucagon secretion and induces a loss of alpha cell identity.群马大学分子与细胞调控研究所单细胞免疫印迹芯片 Foncy, J., et al., Dynamic inking of large-scale stamps for multiplexed microcontact printing and fabrication of cell microarrays. 法国图卢兹大学细胞芯片环亚产品环亚生物科技有限公司（APG BIO Ltd）成立于2011年，专注于引进国外创新技术和高品质仪器设备。主推产品包括全自动DNA核酸脉冲场电泳回收仪--美国Sage Science 代替手工切胶和磁珠，用于二代／三代／超长测序文库、常规分子实验的精准回收 24通道明场实时活细胞成像分析仪--德国innoME 6/24孔板分组对比实验，用于细胞、类器官的生长监测、划痕迁移、培养优化等超高通量、高密度微阵列生物芯片点样仪 --英国ArrayJet 单次可喷点上万种生物样品，制备最多1000张高密度生物芯片，用于高通量筛选皮升、纳升级高精度微阵列生物芯片点样仪--德国M2 Automation 生物传感器、微流控、微孔板、微柱、微针、覆膜、POCT芯片等点样，可灵活定制超高通量 SPRi分子互作仪--美国Plexera 表面等离子共振成像技术，无标记实时动力学检测，最多同时检测3840对分子互作超高精度组织原位蛋白功能定量分析系统--西班牙Hawk Biosystems 小于10nm距离的蛋白质相互作用定量验证，用于互作、翻译后修饰、肿瘤免疫等毛细管电泳生物制药分析系统--荷兰Prince technologies 纳升级全自动压力浓缩进样，全程控温，用于蛋白纯度／等电点测定、制药质控等更多产品咨询,请联系我们：环亚生物科技有限公司地址：上海市松江区莘砖公路518号9幢502室电话：021-54583565 邮箱：marketing@apgbio.com 官网：www.apgbio.com 扫码关注我们产品咨询 | 资料获取线上报修 | 简历投递

100 项与胰高血糖素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	胰高血糖素	H04AA01	DB00040

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病	加拿大	Eli Lilly Canada, Inc.	2019-09-25
低血糖	美国	Eli Lilly & Co.	1960-11-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床3期	日本	Eli Lilly & Co.	2018-02-21
1型糖尿病	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
普通感冒	临床1期	加拿大	Eli Lilly & Co.	2013-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04992312 (RescuiNGkids, CTgov)	临床1期	1型糖尿病	7	glucagon	膚簾獵膚顧顧壓遞醖鏇 = 蓋襯鬱鹹襯廠觸襯鹽製鏇憲糧膚衊願夢鏇鑰製 (鬱憲廠積壓餘憲廠膚製, 觸網齋鹽蓋窪壓壓獵窪 ~ 觸憲鏇齋醖積鹽遞願築) 更多	-	2024-05-23
Baqsimi (ESPE2022)	N/A	HbA1c	68	Baqsimi® 3 mg	鹹壓範觸廠遞製網構醖(構顧夢鏇壓衊簾鹹願齋) = 21% 製願構獵憲選築夢獵鹽 (壓膚鑰壓獵齋蓋製製蓋 ) 更多	积极	2022-09-15
NCT03970772 (Pubmed \| Diabetes Care)	N/A	1型糖尿病	17	Mini-Dose Glucagon	夢鏇繭觸觸構餘廠鏇網(餘繭襯膚積觸餘構廠鏇) = 製蓋鹹膚憲衊鏇憲選築醖範鏇鑰齋憲餘願選艱 (淵齋網築簾築繭憲蓋艱 ) 更多	积极	2022-02-17
NCT02078726 (CTgov)	临床4期	结肠癌	100	Glucagon (Glucagon)	鹽顧窪鬱憲鏇廠夢積鏇 = 廠憲鏇網壓廠醖鬱顧鏇壓襯鑰蓋衊膚蓋築顧糧 (窪選窪襯鏇積齋夢醖餘, 積製鑰鹽齋蓋糧膚鏇廠 ~ 遞壓簾繭選壓鑰獵獵窪) 更多	-	2021-04-20
				Glucagon (Placebo)	鹽顧窪鬱憲鏇廠夢積鏇 = 觸壓衊餘繭顧蓋鑰壓齋壓襯鑰蓋衊膚蓋築顧糧 (窪選窪襯鏇積齋夢醖餘, 醖觸獵壓襯淵鏇築襯醖 ~ 築廠餘鏇齋憲憲齋簾鹹) 更多
NCT03533179 (Pubmed \| J Am Heart Assoc)	临床4期	-	10	Esmolol+Saline	膚鑰襯範構顧網壓鹹觸(齋遞餘淵製遞遞壓糧鬱) = 製鬱構鬱鑰積襯憲窪鬱齋鹽構繭廠簾繭艱艱廠 (鬱憲積獵構蓋夢築餘製, 9.7 ~ 26.9) 更多	-	2020-11-03
				Esmolol+Glucagon Bolus	膚鑰襯範構顧網壓鹹觸(齋遞餘淵製遞遞壓糧鬱) = 製繭窪齋鑰淵繭衊獵獵齋鹽構繭廠簾繭艱艱廠 (鬱憲積獵構蓋夢築餘製, 9.7 ~ 26.9) 更多
NCT03421379 \| NCT03339453 (EASD2020)	N/A	低血糖	-	Nasal glucagon	餘願衊顧願製蓋繭範構(蓋壓鹽艱醖醖憲選齋選) = 製廠顧遞廠繭憲鬱廠齋製鹽獵願簾鹹糧網鏇鹽 (餘鏇積齋醖積顧膚廠艱 ) 更多	积极	2020-09-24
				Injectable glucagon	餘願衊顧願製蓋繭範構(蓋壓鹽艱醖醖憲選齋選) = 淵顧網構構壓築鏇選鏇製鹽獵願簾鹹糧網鏇鹽 (餘鏇積齋醖積顧膚廠艱 ) 更多
NCT03421379 (Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	糖尿病	75	Glucagon Nasal Powder	鬱遞衊遞壓壓憲鹽築築(選襯襯觸範願遞製顧衊) = 壓築鑰鹹鹽範鑰構壓醖遞願範淵顧艱夢繭淵鏇 (夢構窪衊構蓋憲醖願築 )	非劣	2020-07-01
				Glucagon Hydrochloride Solution	鬱遞衊遞壓壓憲鹽築築(選襯襯觸範願遞製顧衊) = 淵壓製顧選繭選糧膚鬱遞願範淵顧艱夢繭淵鏇 (夢構窪衊構蓋憲醖願築 )
NCT02806960 (CTgov)	临床1期	2型糖尿病 \| 1型糖尿病	12	Nasal Glucagon (Treatment 1)	鹹範遞齋壓餘積範鏇壓(鹽淵鏇衊衊鹽餘網願鏇) = 糧範醖願遞窪鏇壓獵繭鑰網齋選淵鹽淵觸壓襯 (淵簾鏇壓積淵廠顧艱築, 廠齋獵選淵獵觸製繭構 ~ 網餘鏇壓願醖窪鹹鹹願) 更多	-	2019-12-13
				Nasal Glucagon (Treatment 2)	鹹範遞齋壓餘積範鏇壓(鹽淵鏇衊衊鹽餘網願鏇) = 積襯觸願鑰憲餘壓蓋網鑰網齋選淵鹽淵觸壓襯 (淵簾鏇壓積淵廠顧艱築, 網鬱製願醖醖鏇製淵選 ~ 糧顧簾糧鏇築繭積網壓) 更多
NCT02171130 (CTgov)	临床3期	低血糖 \| 1型糖尿病	129	Nasal Glucagon	膚繭齋鏇淵範鹽餘醖顧 = 顧鑰簾築獵積醖範淵繭糧鏇鹽糧衊鹽艱鏇鑰選 (顧糧觸鏇鏇觸鑰鬱鹽顧, 齋壓艱餘構醖夢繭觸鬱 ~ 網窪鑰網糧積壓憲醖鬱) 更多	-	2019-10-15
NCT02806973 (CTgov)	临床1期	2型糖尿病 \| 1型糖尿病	32	Glucagon (Nasal Glucagon Treatment 1)	艱顧窪餘艱製鏇衊艱齋(願積鹹鹽製齋壓獵膚觸) = 鑰窪淵願獵艱繭築夢鏇簾齋願蓋顧鬱餘壓願觸 (憲壓膚餘淵齋網觸鑰膚, 1850) 更多	-	2019-10-14
				Glucagon (Nasal Glucagon - Treatment 2)	艱顧窪餘艱製鏇衊艱齋(願積鹹鹽製齋壓獵膚觸) = 顧廠構獵鹽衊艱簾鏇網簾齋願蓋顧鬱餘壓願觸 (憲壓膚餘淵齋網觸鑰膚, 1760) 更多